TABLE 1.

Baseline demographic and clinical characteristics of 350 participants in the GRAHF Cohort

	All n = 350	ADRB1		GRK5		GNB3		α2c
		Arg389Gly+Gly389Gly n = 236	Arg389Arg n = 111	Gln41Gln n = 192	Leu41Leu+Gln41Leu n = 156	CC+TC n = 166	TT n = 184	ins/ins+ins/del n = 291	del/del n = 53
Age (years) ± SD	57 ± 13	57 ± 13	56 ± 13	58 ± 13	56 ± 12	58 ± 13	57 ± 12	58 ± 13	58 ± 14
Female (%)	40	38	44	43	36	40	40	40	40
NYHA class (%/III/IV)	97/3	97/3	96/4	96/4	97/3	97/3	97/3	97/3	98/2
Ischemic (%)	25	24	27	23	28	26	24	25	28
LVEF ± SD	0.24 ± 0.06	0.24 ± 0.06	0.25 ± 0.07	0.24 ± 0.06	0.24 ± 0.06	0.23 ± 0.07	0.24 ± 0.06	0.24 ± 0.06	0.25 ± 0.06
BP systolic (mmHg)± SD	127 ± 17	127 ± 17	127 ± 17	128 ± 17	125 ± 17	126 ± 18	128 ± 17	127 ± 17	124 ± 16
BP diastolic (mmHg)± SD	77 ± 11	76 ± 11	78 ± 10	77 ± 10	77 ± 11	76 ± 11	77 ± 11	77 ± 10	75 ± 11
ACE inhibitor or ARB (%)	94	93	97	93	96	95	94	94	94
Aldosterone receptor antagonist (%)	36	36	36	38	34	37	35	36	34
β-blocker (%)	84	81	92*	82	86	83	85	84	81
FDCI/H (%)	47	44	51	47	46	48	46	47	43

ACE: angiotensin converting enzyme; ARB: angiotensin II receptor blocker; BP: blood pressure; del: deletion polymorphism of α2c; FD I/H: fixed dose isosorbide dinitrate and hydralazine; ins: insertion (wild type) of α2c; LVEF: Left Ventricular Ejection Fraction; NYHA: New York Heart Association; SD: standard deviation.

^*Percent of Arg389Arg subjects on β-blockers significantly higher than Gly389 subjects, p = 0.007. All other comparisons by genotype not statistically significant.